E-LIB Suche - Ergebnisse für: Von Moos, Roger

1

Olaparib not cost-effective as maintenance therapy for plat..:

Mehra, Tarun ; Lupatsch, Judith E. ; Kössler, Thibaud...
PLOS ONE. 19 (2024) 4 - p. e0301271 , 2024

Link: https://doi.org/10.1371/..

2

Praxisrelevante Auswirkungen für Ärztinnen und Ärzte:

von Moos, Roger ; Borner, Markus ; Roth, Arnaud...
Schweizerische Ärztezeitung. , 2024

Link: https://doi.org/10.4414/..

3

First-line durvalumab in patients with PD-L1 positive, adva..:

Mark, Michael ; Froesch, Patrizia ; Gysel, Katrin...
European Journal of Cancer. 200 (2024) - p. 113600 , 2024

Link: https://doi.org/10.1016/..

4

Completion and publication of clinical trials in a cooperat..:

Hayoz, Stefanie ; Kasenda, Benjamin ; Schenker, Annina Lea...
BMJ Open. 13 (2023) 4 - p. e068490 , 2023

Link: https://doi.org/10.1136/..

5

A multicenter phase II trial of anti-EGFR-immunoliposomes l..:

Mamot, Christoph ; Wicki, Andreas ; Hasler-Strub, Ursula...
Scientific Reports. 13 (2023) 1 - p. , 2023

Link: https://doi.org/10.1038/..

6

Quality of life, effectiveness, and safety of aflibercept p..:

Piringer, Gudrun ; Thaler, Josef ; Anchisi, Sandro...
Journal of Geriatric Oncology. 14 (2023) 8 - p. 101638 , 2023

Link: https://doi.org/10.1016/..

7

Eribulin as first-line treatment in older patients with adv..:

Hasler-Strub, Ursula ; Mueller, Andreas ; Li, Qiyu...
Journal of Geriatric Oncology. 14 (2023) 1 - p. 101372 , 2023

Link: https://doi.org/10.1016/..

8

Safety and anti-tumor activity of lisavanbulin administered..:

Joerger, Markus ; Hundsberger, Thomas ; Haefliger, Simon...
Investigational New Drugs. 41 (2023) 2 - p. 267-275 , 2023

Link: https://doi.org/10.1007/..

9

Outcome and Prognostic Factors of COVID-19 Infection in Swi..:

Joerger, Markus ; Metaxas, Yannis ; Zaman, Khalil...
Cancers. 14 (2022) 9 - p. 2191 , 2022

Link: https://doi.org/10.3390/..

10

Gefhrdung von Patienten- und Versorgungssicherheit:

Herzog-Zwitter, Iris ; von Moos, Roger
Schweizerische Ärztezeitung. , 2022

Link: https://doi.org/10.4414/..

11

Population pharmacokinetic analyses of regorafenib and cape..:

Schmulenson, Eduard ; Bovet, Cédric ; Theurillat, Regula...
British Journal of Clinical Pharmacology. 88 (2022) 12 - p. 5336-5347 , 2022

Link: https://doi.org/10.1111/..

12

SAKK 21/12: a phase II trial of transdermal CR1447 in breas..:

Vetter, Marcus ; Rothgiesser, Karin M ; Li, Qiyu...
Endocrine Oncology. 2 (2022) 1 - p. 9-18 , 2022

Link: https://doi.org/10.1530/..

13

Real-World Evaluation of Quality of Life, Effectiveness, an..:

Hofheinz, Ralf-Dieter ; Anchisi, Sandro ; Grünberger, Birgit...
Cancers. 14 (2022) 14 - p. 3522 , 2022

Link: https://doi.org/10.3390/..

14

Initiation of bone-targeted agents in patients with bone me..:

von Moos, Roger ; Lewis, Katie ; Massey, Lucy...
Bone. 154 (2022) - p. 116243 , 2022

Link: https://doi.org/10.1016/..

15

RE: Real-World Use of Bone Modifying Agents in Metastatic C..:

Mark, Michael ; von Moos, Roger ; Cathomas, Richard..
JNCI: Journal of the National Cancer Institute. 114 (2021) 4 - p. 635-636 , 2021

Link: https://doi.org/10.1093/..